메뉴 건너뛰기




Volumn 49, Issue 6, 2008, Pages 1108-1115

Azotemia associated with use of lenalidomide in plasma cell dyscrasias

Author keywords

Amyloidosis; Fanconi syndrome; Lenalidomide; Multiple myeloma; Nephrotoxicity; Plasma cell dyscrasias

Indexed keywords

ACETYLSALICYLIC ACID; ATORVASTATIN; BORTEZOMIB; DEXAMETHASONE; DOXORUBICIN; ESOMEPRAZOLE; FUROSEMIDE; GLUCOCORTICOID; LENALIDOMIDE; LISINOPRIL; MELPHALAN; PAROXETINE; PREDNISONE; QUETIAPINE; THALIDOMIDE; VALSARTAN; VINCRISTINE;

EID: 46749109302     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190802023707     Document Type: Article
Times cited : (30)

References (17)
  • 2
    • 46749152626 scopus 로고    scopus 로고
    • Williams Hematology, 7th ed McGraw-Hill, New York
    • Jacobsen, D. R., Seldin, D. C. and Buxbaum, J. N. (2006) The amyloidoses. Williams Hematology, 7th ed, pp. 1535-1548. McGraw-Hill, New York
    • (2006) The Amyloidoses , pp. 1535-1548
    • Jacobsen, D.R.1    Seldin, D.C.2    Buxbaum, J.N.3
  • 3
    • 3042756207 scopus 로고    scopus 로고
    • Acquired Fanconi syndrome is an indolent disorder in the absence of overt multiple myeloma
    • Ma, C. X., Lacy, M. Q., Rompala, J. F., Dispenzieri, A., Rajkumar, S. V. Greipp, P. R. et al. (2004) Acquired Fanconi syndrome is an indolent disorder in the absence of overt multiple myeloma. Blood, 104, pp. 40-42.
    • (2004) Blood , vol.104 , pp. 40-42
    • Ma, C.X.1    Lacy, M.Q.2    Rompala, J.F.3    Dispenzieri, A.4    Rajkumar, S.V.5    Greipp, P.R.6
  • 5
    • 33644843725 scopus 로고    scopus 로고
    • Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: Randomised controlled trial
    • Palumbo, A., Bringhen, S., Caravita, T., Merla, E., Capparella, V. Callea, V. et al. (2006) Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: Randomised controlled trial. Lancet, 367, pp. 825-831.
    • (2006) Lancet , vol.367 , pp. 825-831
    • Palumbo, A.1    Bringhen, S.2    Caravita, T.3    Merla, E.4    Capparella, V.5    Callea, V.6
  • 6
    • 0037110625 scopus 로고    scopus 로고
    • A phase II trial of pegylated liposomal doxorubicin, vincristine, and reduced-dose dexamethasone combination therapy in newly diagnosed multiple myeloma patients
    • Hussein, M. A., Wood, L., Hsi, E., Karam, M., Elson, P. and Bukowski, R. M. (2002) A phase II trial of pegylated liposomal doxorubicin, vincristine, and reduced-dose dexamethasone combination therapy in newly diagnosed multiple myeloma patients. Cancer, 95, pp. 2160-2168.
    • (2002) Cancer , vol.95 , pp. 2160-2168
    • Hussein, M.A.1    Wood, L.2    Hsi, E.3    Karam, M.4    Elson, P.5    Bukowski, R.M.6
  • 7
    • 0036839013 scopus 로고    scopus 로고
    • Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma
    • Richardson, P. G., Schlossman, R. L., Weller, E., Hideshima, T., Mitsiades, C. Davies, F. et al. (2002) Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood, 100, pp. 3063-3067.
    • (2002) Blood , vol.100 , pp. 3063-3067
    • Richardson, P.G.1    Schlossman, R.L.2    Weller, E.3    Hideshima, T.4    Mitsiades, C.5    Davies, F.6
  • 8
    • 27744492561 scopus 로고    scopus 로고
    • Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma
    • Rajkumar, S. V., Hayman, S. R., Lacy, M. Q., Dispenzieri, A., Geyer, S. M. Kabat, B. et al. (2005) Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood, 106, pp. 4050-4053.
    • (2005) Blood , vol.106 , pp. 4050-4053
    • Rajkumar, S.V.1    Hayman, S.R.2    Lacy, M.Q.3    Dispenzieri, A.4    Geyer, S.M.5    Kabat, B.6
  • 9
    • 33750607347 scopus 로고    scopus 로고
    • A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma
    • Richardson, P. G., Blood, E., Mitsiades, C. S., Jagannath, S., Zeldenrust, S. R. Alsina, M. et al. (2006) A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood, 108, pp. 3458-3464.
    • (2006) Blood , vol.108 , pp. 3458-3464
    • Richardson, P.G.1    Blood, E.2    Mitsiades, C.S.3    Jagannath, S.4    Zeldenrust, S.R.5    Alsina, M.6
  • 10
    • 33846258025 scopus 로고    scopus 로고
    • The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis
    • Dispenzieri, A., Lacy, M. Q., Zeldenrust, S. R., Hayman, S. R., Kumar, S. K. Geyer, S. M. et al. (2007) The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis. Blood, 109, pp. 465-470.
    • (2007) Blood , vol.109 , pp. 465-470
    • Dispenzieri, A.1    Lacy, M.Q.2    Zeldenrust, S.R.3    Hayman, S.R.4    Kumar, S.K.5    Geyer, S.M.6
  • 11
    • 33846256126 scopus 로고    scopus 로고
    • Lenalidomide and dexamethasone in the treatment of AL amyloidosis: Results of a phase 2 trial
    • Sanchorawala, V., Wright, D. G., Rosenzweig, M., Finn, K. T., Fennessey, S. Zeldis, J. B. et al. (2007) Lenalidomide and dexamethasone in the treatment of AL amyloidosis: Results of a phase 2 trial. Blood, 109, pp. 492-496.
    • (2007) Blood , vol.109 , pp. 492-496
    • Sanchorawala, V.1    Wright, D.G.2    Rosenzweig, M.3    Finn, K.T.4    Fennessey, S.5    Zeldis, J.B.6
  • 13
    • 33749438404 scopus 로고    scopus 로고
    • Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion
    • List, A., Dewald, G., Bennett, J., Giagounidis, A., Raza, A. Feldman, E. et al. (2006) Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med, 355, pp. 1456-1465.
    • (2006) N Engl J Med , vol.355 , pp. 1456-1465
    • List, A.1    Dewald, G.2    Bennett, J.3    Giagounidis, A.4    Raza, A.5    Feldman, E.6
  • 14
    • 3042734357 scopus 로고    scopus 로고
    • Aminoglycoside-associated severe renal failure in patients with multiple myeloma treated with thalidomide
    • Montagut, C., Bosch, F., Villela, L., Rosinol, L. and Blade, J. (2004) Aminoglycoside-associated severe renal failure in patients with multiple myeloma treated with thalidomide. Leuk Lymphoma, 45, pp. 1711-1712.
    • (2004) Leuk Lymphoma , vol.45 , pp. 1711-1712
    • Montagut, C.1    Bosch, F.2    Villela, L.3    Rosinol, L.4    Blade, J.5
  • 15
    • 0037359277 scopus 로고    scopus 로고
    • Tolerability and efficacy of thalidomide for treatment of patients with AL amyloidosis
    • Selden, D. C., Choufani, E. B., Dember, L. M., Wiesman, J., Berk, J. L. Falk, R. H. et al. (2003) Tolerability and efficacy of thalidomide for treatment of patients with AL amyloidosis. Clin Lymphoma, 3, pp. 241-246.
    • (2003) Clin Lymphoma , vol.3 , pp. 241-246
    • Selden, D.C.1    Choufani, E.B.2    Dember, L.M.3    Wiesman, J.4    Berk, J.L.5    Falk, R.H.6
  • 16
    • 15944395687 scopus 로고    scopus 로고
    • The combination of thalidomide and intermediate-dose dexamethasone is an effective but toxic treatment for patients with primary amyloidosis (AL)
    • Palladini, G., Perfetti, V., Perlini, S., Obici, L., Lavatelli, F. Caccialanza, R. et al. (2005) The combination of thalidomide and intermediate-dose dexamethasone is an effective but toxic treatment for patients with primary amyloidosis (AL). Blood, 105, pp. 2949-2951.
    • (2005) Blood , vol.105 , pp. 2949-2951
    • Palladini, G.1    Perfetti, V.2    Perlini, S.3    Obici, L.4    Lavatelli, F.5    Caccialanza, R.6
  • 17
    • 36148973115 scopus 로고    scopus 로고
    • Pharmacokinetics of lenalidomide in subjects with various degrees of renal impairment and in subjects on hemodialysis
    • Chen, N., Lau, H., Kong, L., Kumar, G., Zeldis, J. B. Knight, R. et al. (2007) Pharmacokinetics of lenalidomide in subjects with various degrees of renal impairment and in subjects on hemodialysis. J Clin Pharmacol, 47, pp. 1466-1475.
    • (2007) J Clin Pharmacol , vol.47 , pp. 1466-1475
    • Chen, N.1    Lau, H.2    Kong, L.3    Kumar, G.4    Zeldis, J.B.5    Knight, R.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.